We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02337309
Recruitment Status : Terminated (Low patient accrual)
First Posted : January 13, 2015
Last Update Posted : August 20, 2018
SignalRX Pharmaceuticals, Inc.
University of Southern California
Information provided by (Responsible Party):
New Approaches to Neuroblastoma Therapy Consortium

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 22, 2018
Actual Study Completion Date : May 22, 2018